Corcept Therapeutics (CORT) Competitors

Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, community ranking, risk, valuation, profitability, institutional ownership and earnings.

Is RPRX or CORT more profitable?

Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Royalty Pharma	37.94%	24.40%	14.01%
Corcept Therapeutics	22.35%	24.54%	20.24%

Which has preferable earnings & valuation, RPRX or CORT?

Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Royalty Pharma	$2.26B	8.22	$858.98M	$1.45	22.27
Corcept Therapeutics	$675.04M	10.54	$106.14M	$1.24	54.38

Do insiders & institutionals have more ownership in RPRX or CORT?

54.3% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are owned by institutional investors. 18.9% of Royalty Pharma shares are owned by insiders. Comparatively, 20.5% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Does the MarketBeat Community believe in RPRX or CORT?

Corcept Therapeutics received 221 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.37% of users gave Corcept Therapeutics an outperform vote while only 67.99% of users gave Royalty Pharma an outperform vote.

Company	Underperform	Outperform
Royalty Pharma	Outperform Votes 325 67.99%	Underperform Votes 153 32.01%
Corcept Therapeutics	Outperform Votes 546 71.37%	Underperform Votes 219 28.63%

Which has more risk & volatility, RPRX or CORT?

Royalty Pharma has a beta of 0.5, meaning that its share price is 50% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.15, meaning that its share price is 85% less volatile than the S&P 500.

Do analysts prefer RPRX or CORT?

Royalty Pharma currently has a consensus target price of $42.50, suggesting a potential upside of 31.62%. Corcept Therapeutics has a consensus target price of $143.25, suggesting a potential upside of 112.44%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Royalty Pharma	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Corcept Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media refer more to RPRX or CORT?

In the previous week, Corcept Therapeutics had 3 more articles in the media than Royalty Pharma. MarketBeat recorded 23 mentions for Corcept Therapeutics and 20 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.37 beat Corcept Therapeutics' score of 1.15 indicating that Royalty Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Royalty Pharma	15 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	14 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Corcept Therapeutics beats Royalty Pharma on 11 of the 18 factors compared between the two stocks.